Pancreatic Cancer’s Stealth Mechanism Exposed, Offering New Hope for Treatment

Scientists have uncovered a hidden strategy pancreatic cancer uses to evade the immune system, potentially paving the way for more effective therapies. Researchers have identified a molecular process that allows the aggressive cancer to remain undetected, and disrupting this process led to significant tumor shrinkage in animal models.

How Pancreatic Cancer Hides from the Immune System

A team of international researchers, led by scientists at the University of Würzburg (JMU) in Germany, the Massachusetts Institute of Technology (USA), and Würzburg University Hospital, has pinpointed a key mechanism that allows pancreatic cancer cells to avoid immune detection. The findings, published in the journal Cell, center around a protein called MYC.

MYC is well-known as a driver of tumor growth, prompting cells to divide and multiply rapidly. However, researchers discovered MYC has a second, unexpected role: suppressing immune alarm signals. Under stressful conditions within rapidly expanding tumors, MYC changes its behavior, binding to newly formed RNA molecules instead of DNA.

This shift triggers a chain reaction. MYC proteins cluster together, forming structures that attract and concentrate the exosome complex. The exosome complex then breaks down RNA-DNA hybrids, which are normally strong signals alerting the immune system to abnormal activity within cells. By removing these hybrids, MYC effectively silences the immune response, allowing the tumor to grow unnoticed.

Blocking the Stealth Mechanism Leads to Tumor Collapse

To test the importance of this process, researchers engineered MYC proteins unable to bind to RNA. In animal models, tumors with the defective MYC protein shrank by 94% within 28 days – but only in animals with intact immune systems. This demonstrated that restoring the immune system’s ability to recognize the tumor led to a dramatic reduction in tumor size.

A New Approach to Cancer Therapy

Current attempts to block MYC directly have been challenging due to its essential role in normal cells. Completely shutting down MYC can cause harmful side effects. However, the newly identified mechanism offers a more targeted approach.

“Instead of completely switching off MYC, future drugs could specifically inhibit only its ability to bind RNA,” explains Martin Eilers, Chair of Biochemistry and Molecular Biology at JMU. “This would potentially abandon its growth-promoting function untouched, but lift the tumor’s cloak of invisibility,” allowing the immune system to attack the cancer cells.

Future Research and Collaboration

While these laboratory results are promising, researchers caution that clinical applications are still years away. Further research is needed to understand how immune-activating RNA-DNA hybrids exit the cell nucleus and how MYC’s RNA-binding activity affects the surrounding tumor environment.

The research was supported by funding from Cancer Research UK, the Children Cancer Free Foundation (Kika), and the French National Cancer Institute (INCa) through the Cancer Grand Challenges initiative, as well as an Advanced Grant from the European Research Council.

Dr. David Scott, Director of Cancer Grand Challenges, emphasized the importance of international collaboration in tackling complex cancer challenges. “Research like this shows how uncovering the mechanisms tumors use to hide from the immune system can open up new possibilities, not only for adult cancers but as well for childhood cancers,” he stated.

Key Takeaways

• Pancreatic cancer employs a stealth mechanism involving the MYC protein to evade the immune system.
• MYC suppresses immune alarm signals by breaking down RNA-DNA hybrids.
• Blocking MYC’s ability to bind RNA led to significant tumor shrinkage in animal models.
• This discovery opens the door for developing more targeted therapies that selectively disrupt the cancer’s immune evasion strategy.